Bliley PM
[Memo Regarding] Subject: CTR
Abstract
Reports concern and discussion among industry lawyers regarding "trends at [the Council for Tobacco Research]." Alleges discontinuing the "mouse work with susceptibility strains" and "all work with tobacco fractions". Verifies continuation of "work exposing mice to whole tobacco smoke" and continuation of nicotine study and attests to the importance of determining "how nicotine acts in the brain." States that "work with AHH" was not producing definitive results due to variability. Remarks that it was unsure whether Dr. Abood was to develop "an antagonist for nicotine" and that Alex Holtzman would follow up.
Fields
- Type
- Memorandum
- Author
- Seligman, Robert B. (PM VP of R&D c. 1976-82)Vice President of Research and Development at Philip Morris Richmond, VA 1976-1982. Reported to Senior Vice President of Operations. In 1982 transferred to tobacco technology group. Wanted to share ammonia and other tobacco technology with PM International companies.
- Recipient
- File
General counsel for B&W. CTR Chairman/President 1975-1981
Outside research on nicotine analogs for PM. University of Rochester. Around 1980.
Created and funded by the tobacco industry to award grants to study of the link between smoking and disease. Part of a four decade effort to cast doubt on the links between smoking and disease.
See Philip Morris Incorporated
Document Images
From:
Su bj ect:
PHILIP HORRIS U. S. A.
INTER-OFFICE CORRESPONDENCE
RI CHNOND, V'IRGIHIA
File
R. B. Seligman
CTR
Date:
January 13, 1978
On January 12, 1978, the writer was contacted
by Alex Holtzman concerning the discussion the
industry's lawyers had about CTR. Evidently, the other
companies were as concerned aswe were about the trends
at CTR. A representation (Pebbles and Rhomer) went to
see Ad Yeaman. Mr. Yeaman indicated the following:
The mouse work with susceptibility
strains has been discontinued.
All work with tobacco fractions
has been discontinued.
Work exposing mice to whole tobacco
smoke continued.
The work with AHH appears to be
producing no definitive results.
Results are too variable and
the total seems~to be grinding
to ahalt.
Mr. Yeaman felt the nicotine work
should be continued because it is
important to find the binding
centers in the brain to determine
how nicotine acts in the brain.
The writer questioned Alex Holtzman concerning
the development of an antagonist for nicotine resulting
from the contract with Dr. Abood. Alex Holtzman was to
check, but he felt the development of an antagonist was
not included in the charge given to Dr. Abood.
RBS/sgr
cc: Dr. T. S. Osdene
